Statera Biopharma, Inc. (STAB): BCG Matrix [Dec-2025 Updated]

Let's cut right to it: analyzing Statera Biopharma, Inc. through the Boston Consulting Group framework reveals a micro-cap in deep distress as of late 2025, not just a tough spot. You won't find any Stars or Cash Cows here; the trailing revenue of just $3.69 million confirms that the company lacks any established product engine. The common stock trading around $0.0001 and the -$91.83 million net loss firmly place the corporate entity in the Dog quadrant, while the entire future rests on high-risk Question Marks like STAT-201, which demands a -$12.19 million free cash flow burn to fund. Dive in below to see exactly where the capital is tied up in this precarious R&D situation.

Background of Statera Biopharma, Inc. (STAB)

You're looking at Statera Biopharma, Inc. (STAB), which, as of late 2025, is operating as a clinical-stage biopharmaceutical company. The core of their mission is developing next-generation immune therapies aimed at immune restoration and homeostasis, moving away from single-target approaches. They build their work on a proprietary platform they call the Advanced Immunomodulating Multi-component System, or AIMS, which is designed to rebalance the body's immune system to treat complex conditions like autoimmune disorders, cancers, and emerging viruses.

Honestly, the financials tell a story typical of a company deep in the development phase. Looking at the trailing twelve months (TTM) data leading up to November 2025, Statera Biopharma, Inc. posted revenue of $3.69M. However, the bottom line shows significant investment, with a Net Income TTM of -$91.84M and Free Cash Flow TTM of -$12.19M. To give you some context on revenue trajectory, their 3-year Revenue CAGR sits at a strong 54.99%, though the 5-year CAGR is a more modest 12.25%. The company is trading at a very low price point, around $0.0001 per share, with a reported market cap of just $7,258.

When we map out their product portfolio, we see several late-stage developmental candidates emerging from that AIMS platform. Their most advanced asset, STAT-201, is focused on treating moderate to severe Crohn's Disease in pediatric patients, with plans for a Phase 3 clinical trial. Then there's STAT-205, which is being evaluated for both acute and post-acute COVID-19, aiming to modulate the immune system response in those patients. Beyond those, the pipeline includes work on Entolimod for hematology issues and STAT-401 for pancreatic cancer, plus they've signaled potential expansion into areas like fibromyalgia and multiple sclerosis. That's the landscape you're dealing with-a high-potential, high-burn clinical pipeline.

Statera Biopharma, Inc. (STAB) - BCG Matrix: Stars

You're looking at the Stars quadrant for Statera Biopharma, Inc. as of late 2025, and honestly, the picture is quite clear: Statera Biopharma, Inc. has no products currently categorized as Stars.

Stars are those products with a high market share in a market that is growing fast. They are the leaders, but they burn cash to maintain that lead. If Statera Biopharma, Inc. had a Star, you'd expect to see significant revenue and market dominance in a rapidly expanding therapeutic area. The company lacks any approved therapeutic with both high market share and high market growth.

The most significant recent event impacting this quadrant was the licensing of the late-stage asset Entolimod to Tivic Health in February 2025, which effectively removed the most likely candidate for future Star status from Statera Biopharma, Inc.'s direct portfolio. This move shifted the potential growth asset out of Statera Biopharma, Inc.'s direct control and into Tivic Health's pipeline.

To put this in perspective, consider the asset that was licensed. Entolimod was licensed for Acute Radiation Syndrome (ARS), a market estimated at USD 5.2 billion in 2024, with a projected compound annual growth rate of five percent through 2031. Tivic Health later exercised an option for the Neutropenia indication in March 2025, a market estimated to exceed $20 billion by 2029. That's significant market potential that Statera Biopharma, Inc. is now positioned to benefit from via royalties and milestones, not as a direct Star performer.

The current market capitalization of approximately $7 thousand as of late 2025 confirms the absence of a high-share, high-growth product line currently driving significant enterprise value. Here's a quick look at some of the recent financial context:

The strategic shift is evident when you review the asset's prior development status. The Entolimod program had already seen over forty animal and human trials, with an investment of $140 million prior to the licensing deal. That level of investment is typical for a product nearing Star status, but its transfer means Statera Biopharma, Inc. is currently positioned differently.

The current operational reality for Statera Biopharma, Inc. suggests a focus away from direct Star management, as reflected by its financial metrics:

• Current Ratio: 0.05
• Return on Equity (ROE): -286.94%
• Operating Cash Flow (Last 12 Months): -$12.09 million
• Initial Payment from Tivic Health: $1,200,000 in equity and $300,000 cash for the ARS license

If onboarding takes 14+ days, churn risk rises, but here, the risk is that the company isn't managing a high-growth, high-share asset directly.

Finance: draft 13-week cash view by Friday.

Statera Biopharma, Inc. (STAB) - BCG Matrix: Cash Cows

You're looking at the Cash Cow quadrant of the Boston Consulting Group Matrix for Statera Biopharma, Inc. as of late 2025, but honestly, the data shows this quadrant is empty for the company right now. A Cash Cow is a market leader in a mature, low-growth space that prints cash; Statera Biopharma, Inc. is the opposite-a clinical-stage biopharma firm focused entirely on research and development (R&D).

Statera Biopharma, Inc. has no established Cash Cow products generating stable, high-margin revenue. The business model is pure R&D, not commercial, so a Cash Cow is not a near-term possibility. Their revenue stream, which stood at approximately $3.69 million for the trailing twelve months (TTM) leading up to the August 14, 2025, earnings report, is highly dependent on non-recurring licensing and collaboration payments, not steady product sales. This lumpy revenue profile is the antithesis of the stable cash flow required for a Cash Cow.

The sheer scale of the losses confirms the lack of internal cash generation. Trailing 12-month revenue of only $3.69 million is insufficient to cover operating costs, let alone fund the pipeline. Here's the quick math on the operational deficit:

Even though the Gross Profit Margin was reported at a relatively strong 70.19% TTM, the massive operating expenses associated with clinical development drive the overall picture into deep negative territory, resulting in a Net Profit Margin of roughly -2488.62%. You can see the cash consumption clearly in the cash flow statement; the company burned through cash to support operations.

The balance sheet confirms this severe liquidity crunch. A current ratio of 0.05 shows severe liquidity issues, meaning no internal cash generation is happening to meet short-term obligations. This ratio means that for every dollar in current liabilities, Statera Biopharma, Inc. only has five cents in current assets to cover it. The net cash position was reported as a deficit of -$6.90 million, with cash on hand at just $506,098.

When you evaluate the financial position, you see a company that is consuming capital, not generating it. This is typical for a clinical-stage entity, but it disqualifies it from the Cash Cow category entirely. The key financial indicators that define a Cash Cow-high market share in a mature market leading to high, stable profit margins and positive free cash flow-are absent. Instead, you have:

• TTM Revenue: $3.69 million.
• Current Ratio: 0.05.
• Negative Free Cash Flow: -$12.19 million.
• Business Model: Pure R&D, clinical-stage.
• Shares Outstanding: 72.58 million.

For Statera Biopharma, Inc., the focus must be on managing the Question Marks in the pipeline, as there are no established Cash Cows to 'milk' for funding. Finance: draft 13-week cash view by Friday.

Statera Biopharma, Inc. (STAB) - BCG Matrix: Dogs

Dogs are business units or products characterized by low market share in low-growth markets. For Statera Biopharma, Inc., the evidence strongly suggests that the entire corporate entity, when viewed through the lens of the Boston Consulting Group (BCG) Matrix, falls squarely into this quadrant, indicating minimal current cash generation and high resource consumption relative to returns.

The common stock (STAB) is a Dog, trading around $0.0001 per share on the OTC Pink Open Market in December 2025. This price point reflects minimal market valuation and liquidity, consistent with a low-share-price, low-growth security.

The overall corporate entity is a Dog, evidenced by a 12-month net loss of -$91.83 million. This substantial loss, paired with trailing twelve-month revenue of only $3.69 million, illustrates a significant negative operating leverage that traps capital rather than generating it.

Legacy pipeline assets that have stalled or been deprioritized, consuming resources without clear advancement, are classic Dog characteristics in a biotech context. For instance, the STAT-201 program for pediatric Crohn's Disease had planned for a Phase 3 trial initiation in mid-2023, and STAT-401 for pancreatic cancer targeted a trial in the first half of 2022. The lack of reported progress beyond these long-past target dates suggests these assets are not currently driving growth or capturing significant market share.

The negative evaluation and -286.94% Return on Equity (ROE) firmly place the company's core operations in the Dog quadrant. This severe negative ROE indicates that the company is destroying shareholder equity through its operations, a hallmark of a unit that should be minimized or divested.

Here's a quick look at the key financial metrics that define this Dog status as of late 2025:

The operational fragility is further highlighted by key financial ratios, which suggest high risk and low operational efficiency:

• Current Ratio: 0.05
• Quick Ratio: 0.04
• Altman Z-Score: -21.97
• Shares Outstanding: 72.58 million
• Free Cash Flow (TTM): -$12.19 million

The strategy for Dogs is avoidance and minimization. Expensive turn-around plans usually do not help, so capital tied up in these areas, like the older pipeline programs, should be considered for divestiture or complete cessation of further investment to conserve scarce resources.

Statera Biopharma, Inc. (STAB) - BCG Matrix: Question Marks

You're looking at Statera Biopharma, Inc. (STAB) assets that are in high-growth markets but currently hold a low relative market share. These are the Question Marks, the cash consumers of the portfolio. They demand significant capital to fight for market position, but right now, they aren't delivering much return. Honestly, these business units are losing the company money in the near term, but they hold the potential to become Stars if the investment pays off and market share grows quickly.

STAT-201 for pediatric Crohn's disease is a prime example here. This candidate has secured Orphan Drug Designation from the FDA for treating pediatric patients with Crohn's Disease. Statera Biopharma completed an end of Phase 2 meeting with the FDA regarding the clinical development plan for a Phase 3 trial, with plans previously stated to initiate this trial in 2022, and later planning for mid-2023. The need is clear, as CD patients endure significant physical, emotional, and economic burdens, and STAT-201 targets the restoration of mucosal healing and intestinal barrier function.

Next, consider STAT-205, targeting acute and post-acute COVID-19. While the acute market has become crowded, the post-acute segment, or Post-Acute COVID-19 Syndrome (PACS), represents a high unmet need, as roughly 30% of all COVID-19 infections reportedly develop into long-haul syndrome. Statera Biopharma initiated a clinical trial in acute COVID and was planning a study for PACS patients. This asset requires heavy funding to secure a foothold in this rapidly evolving infectious disease space.

The entire Advanced Immunomodulating Multi-component System (AIMS) platform itself is a Question Mark. This core development platform is what underpins STAT-201 and STAT-205, and it requires massive, sustained investment to validate its ability to harmonize the immune orchestra by targeting complex pathways, rather than a single target approach.

The strategic move to pivot into diagnostics via the planned merger with Worksite Labs, announced via a Letter of Intent on March 15, 2023, also fits this quadrant. Worksite Labs reported revenues of over $50 million for the period ended 2022. However, the current status of this transaction remains unclear, making the expected strategic benefit and integration a significant unknown variable requiring heavy management focus.

Here's a quick look at the data points associated with these high-risk, high-growth assets:

The cash demands of managing these pipeline assets and strategic pivots are evident in the company's operating performance. You need to fund the R&D and the potential acquisition integration, so the burn rate is high. Statera Biopharma's financial reality reflects this investment need:

• The company has a Free Cash Flow of -$12.19 million over the last 12 months.
• Operating Cash Flow for the same period was -$12.09 million.
• Capital Expenditures over the last 12 months were -$103,367.
• The Return on Equity (ROE) stands at -286.94%.
• The Return on Assets (ROA) is -23.85%.

The path forward for these Question Marks is binary: either Statera Biopharma invests heavily to rapidly increase market share for one or more of these candidates, or they risk them becoming Dogs. Finance: draft 13-week cash view by Friday.